SCHEMBL15977804

SCHEMBL15977804

c1cnc(-c2ccc3c(-c4cc5ccccc5c5ccccc45)c4ccccc4c(-c4cc5ccccc5c5ccccc45)c3c2)nc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP11B1 P15538 1/20 0.44
NISCH Q9Y2I1 1/20 0.39
LMNA P02545 3/20 0.37
HPGD P15428 3/20 0.37
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
MAPK1 P28482 3/20 0.36
CYP3A4 P08684 2/20 0.36
MAPT P10636 1/20 0.36
APEX1 P27695 1/20 0.36
PMP22 Q01453 1/20 0.36
SOS1 Q07889 1/20 0.35
HPRT1 P00492 1/20 0.35
ALDH1A1 P00352 3/20 0.35
HIF1A Q16665 3/20 0.35
HSD17B10 Q99714 2/20 0.35
L3MBTL1 Q9Y468 2/20 0.35
TSHR P16473 1/20 0.35
CASP1 P29466 1/20 0.35
PIK3CD O00329 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15977807 0.94 CYP11B1 (0.43) CYP11B1NISCHLMNAHPGDMEN1
SCHEMBL15977566 0.94 CYP11B1 (0.43) CYP11B1NISCHLMNAHPGDMEN1
SCHEMBL15977504 0.93 CYP11B1 (0.39) CYP11B1NISCHLMNAHPGDMAPK1
SCHEMBL15977915 0.92 CYP11B1 (0.38) CYP11B1NISCHLMNAHPGDMEN1
SCHEMBL15977756 0.85 NPC1 (0.46) CYP11B1LMNAHPGDMEN1KMT2A
SCHEMBL12263024 0.85 CYP11B1 (0.46) CYP11B1NISCHLMNAHPGDMEN1
SCHEMBL15977707 0.84 HTR2C (0.43) NISCHLMNAHPGDMEN1KMT2A
SCHEMBL10301147 0.84 CYP11B1 (0.44) CYP11B1NISCHLMNAHPGDMEN1
SCHEMBL15977850 0.83 NPC1 (0.44) CYP11B1LMNAHPGDMEN1KMT2A
SCHEMBL15977770 0.83 NPC1 (0.44) CYP11B1LMNAHPGDMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220416178-A1 COMPOSITION, ORGANIC ELECTROLUMINESCENCE DEVICE, AND ELECTRONIC APPARATUS IDEMITSU KOSAN CO.,LTD. (JP) 2022-12-29 US disclosed
US-9559311-B2 Anthracene derivative, organic-electroluminescence-device material, organic electroluminescence device, and electronic equipment IDEMITSU KOSAN CO., LTD. (JP) 2017-01-31 US disclosed
US-9559311-B2 Anthracene derivative, organic-electroluminescence-device material, organic electroluminescence device, and electronic equipment IDEMITSU KOSAN CO., LTD. (JP) 2017-01-31 US disclosed
US-20140239273-A1 ANTHRACENE DERIVATIVE, ORGANIC-ELECTROLUMINESCENCE-DEVICE MATERIAL, ORGANIC ELECTROLUMINESCENCE DEVICE, AND ELECTRONIC EQUIPMENT IDEMITSU KOSAN CO., LTD. (JP) 2014-08-28 US disclosed
US-20140239273-A1 ANTHRACENE DERIVATIVE, ORGANIC-ELECTROLUMINESCENCE-DEVICE MATERIAL, ORGANIC ELECTROLUMINESCENCE DEVICE, AND ELECTRONIC EQUIPMENT IDEMITSU KOSAN CO., LTD. (JP) 2014-08-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220416178-A1 COMPOSITION, ORGANIC ELECTROLUMINESCENCE DEVICE, AND ELECTRONIC APPARATUS PIEZO1, TMEM109, SLC39A14 CYP11B1 1241/4885NISCH 2960/4885LMNA 1370/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.